59694-0 |
Hydroxytriazolam |
MCnt |
Meconium |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxytriazolam [Mass/mass] in Meconium by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59694-0 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-Triazolam Mec Cfm-mCnt |
|
|
|
N |
|
Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Hydroxy triazolam; Illicit; LC/MS/MS; Mass content; Mec; OH-Triazolam; OHTRZ; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Triazolam metabolite |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59695-7 |
Hydroxytriazolam |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Hydroxytriazolam [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59695-7 |
|
|
|
|
Both |
|
|
|
0 |
OH-Triazolam Tiss-mCnt |
|
|
|
N |
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Hydroxy triazolam; Illicit; Mass Content; OH-Triazolam; OHTRZ; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified; Triazolam metabolite |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59696-5 |
Hydroxytriazolam |
MCnt |
Tiss |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxytriazolam [Mass/mass] in Tissue by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59696-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-Triazolam Tiss Cfm-mCnt |
|
|
|
N |
|
Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Hydroxy triazolam; Illicit; LC/MS/MS; Mass content; OH-Triazolam; OHTRZ; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified; Triazolam metabolite |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59697-3 |
Iodide |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Iodide [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
1 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59697-3 |
|
|
|
|
Both |
|
|
|
0 |
Iodide SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.34 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59699-9 |
LORazepam |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
LORazepam [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59699-9 |
|
|
|
|
Both |
|
|
|
0 |
LORazepam Bld-mCnc |
|
|
|
N |
|
Addiction; Ativan; Blood; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
597-5 |
Bacteria |
Prid |
Asp |
Pt |
Nom |
Aerobic culture |
|
ACTIVE |
Bacteria identified in Aspirate by Aerobe culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
597-5 |
|
Aerobic culture |
|
|
Both |
|
|
|
0 |
Bacteria Aspirate Aerobe Cult |
|
|
|
|
|
Aerobe; Aerobe Cult; Aerobed; Aspirate; Bact; C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random |
2.78 |
1 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
5970-9 |
Plasminogen |
ACnc |
PPP |
Pt |
Qn |
Chromo |
|
ACTIVE |
Plasminogen [Units/volume] in Platelet poor plasma by Chromogenic method |
|
MIN |
DefinitionDescription |
|
|
CTA U/mL |
|
|
|
|
|
|
COAG |
|
5970-9 |
|
Chromo |
|
|
Both |
|
|
|
0 |
PLG PPP Chro-aCnc |
|
|
|
Y |
|
Arbitrary concentration; Chromogenic assay; COAGULATION; ENZY; Enzymatic assay; Hematology; Heme; Plas; Platelet poor plasma; PLG; PLGN; Point in time; Profibrinolysin; QNT; Quan; Quant; Quantitative; Random |
2.73 |
1.0d |
|
|
|
|
|
|
|
{CTA'U}/mL |
|
|
|
0 |
59700-5 |
LORazepam |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
LORazepam [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59700-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
LORazepam Bld Cfm-mCnc |
|
|
|
N |
|
Addiction; Ativan; Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59701-3 |
LORazepam |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
LORazepam [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59701-3 |
|
|
|
|
Both |
|
|
|
0 |
LORazepam Fld-mCnc |
|
|
|
N |
|
Addiction; Ativan; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Fl; Fld; FLU; Fluid; Illicit; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59702-1 |
LORazepam |
MCnc |
Body fld |
Pt |
Qn |
Confirm |
|
ACTIVE |
LORazepam [Mass/volume] in Body fluid by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59702-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
LORazepam Fld Cfm-mCnc |
|
|
|
N |
|
Addiction; Ativan; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Fl; Fld; FLU; Fluid; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59703-9 |
LORazepam |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
LORazepam [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59703-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
LORazepam SerPl Cfm-mCnc |
|
|
|
N |
|
Addiction; Ativan; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59704-7 |
LORazepam |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
LORazepam [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59704-7 |
|
|
|
|
Both |
|
|
|
0 |
LORazepam Tiss-mCnt |
|
|
|
N |
|
Addiction; Ativan; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Mass Content; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59705-4 |
Methadone |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Methadone [Presence] in Serum or Plasma by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
25 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59705-4 |
|
Screen |
|
|
Both |
|
|
|
0 |
Methadone SerPl Ql Scn |
|
|
|
N |
|
Addiction; Dolophin; Dolophine; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; METD; Methadose; MTD; Ordinal; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.32 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
59706-2 |
MethylePHEDrine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
MethylePHEDrine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59706-2 |
|
|
|
|
Both |
|
|
|
0 |
Me-ePHEDrine SerPl-mCnc |
|
|
|
N |
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Ivilco; Level; Mass concentration; Me-ePHEDrine; Pholcomed; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tossamine plus |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59707-0 |
Midazolam |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Midazolam [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59707-0 |
|
|
|
|
Both |
|
|
|
0 |
Midazolam Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Versed; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59708-8 |
Midazolam |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Midazolam [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59708-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Midazolam Bld Cfm-mCnc |
|
|
|
N |
|
Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Versed; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59709-6 |
Midazolam |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Midazolam [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59709-6 |
|
|
|
|
Both |
|
|
|
0 |
Midazolam Fld-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Versed |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
5971-7 |
Plasminogen activator tissue type Ag |
MCnc |
PPP |
Pt |
Qn |
IA |
|
ACTIVE |
Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
COAG |
|
5971-7 |
|
IA |
|
|
Both |
|
|
|
0 |
tPA Ag PPP IA-mCnc |
|
|
|
Y |
|
Antigen; Antigens; Blood plasminogen activator; COAGULATION; EIA; ELFA; ELISA; Enzyme immunoassay; Hematology; Heme; IAA; Level; Mass concentration; MEIA; Plas; Platelet poor plasma; PLG; PLGN; Point in time; Profibrinolysin; QNT; Quan; Quant; Quantitative; Random; SUDS; Tissue plasminogen activator; TPA; t-PA; Vascular plasminogen activator |
2.73 |
1.0d |
|
|
|
|
|
|
|
ug/L |
|
|
Renamed Method from "Imm" to "IA" for consistency across classes (approved by Laboratory LOINC Committee 2016 12). |
0 |
59710-4 |
Midazolam |
MCnc |
Body fld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Midazolam [Mass/volume] in Body fluid by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59710-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Midazolam Fld Cfm-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Versed |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59711-2 |
Midazolam |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Midazolam [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59711-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Midazolam SerPl Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Versed |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59712-0 |
Midazolam |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Midazolam [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59712-0 |
|
|
|
|
Both |
|
|
|
0 |
Midazolam Tiss-mCnt |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Mass content; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified; Versed |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59713-8 |
Midazolam |
MCnt |
Tiss |
Pt |
Qn |
Confirm |
|
ACTIVE |
Midazolam [Mass/mass] in Tissue by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59713-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Midazolam Tiss Cfm-mCnt |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass content; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified; Versed |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59714-6 |
Nitrous oxide |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Nitrous oxide [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
1.8 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59714-6 |
|
|
|
|
Both |
|
|
|
0 |
N2O Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Laughing gas; Level; Mass concentration; N2O; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59715-3 |
Nitrous oxide |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Nitrous oxide [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
1.8 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59715-3 |
|
|
|
|
Both |
|
|
|
0 |
N2O SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Laughing gas; Level; Mass concentration; N2O; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59716-1 |
Nordiazepam |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Nordiazepam [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59716-1 |
|
|
|
|
Both |
|
|
|
0 |
Nordiazepam Bld-mCnc |
|
|
|
N |
|
Blood; Calmday; Chlordiazepoxide metabolite; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; Level; Madar; Mass concentration; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Point in time; Praxadium; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Stilny; Tranxilium N; Vegesan; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |